ClinicalTrials.gg
CompletedNCT07265336Updated Jul 16, 2026

Excess Base Comparison Between Pregnant Subjects With Severe Preeclampsia vs. Normotensive Pregnant Women

An interventional study of Arterial Blood gases in Preeclampsia and Severe Preeclampsia, sponsored by Saint Thomas Hospital, Panama. Completed at 1 site in Panama. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Saint Thomas Hospital, Panama · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Sex
Female
01

Study summary

The study's primary goal is to compare the base excess (BE) values-an indicator of metabolic changes-in two groups of patients at Santo Tomás Hospital: those with severe preeclampsia and healthy, pregnant individuals. Researchers will measure these values using an arterial blood gas test before delivery or surgery.

This is a prospective cohort study. The researchers will analyze various blood gas parameters, including pH, lactate, and BE, and then correlate the BE values with clinical variables and negative maternal outcomes.

The expected outcome is that a abnormal BE values will be linked to a greater severity of preeclampsia. If this association is confirmed, BE could serve as an additional marker for predicting the severity of the condition and may lay the groundwork for future research on diagnostic and therapeutic standards based on blood gas analysis.

02

Conditions studied

  • Preeclampsia
  • Severe Preeclampsia

Browse trials for

Keywords

  • Excess base
  • Severe preeclampsia
  • Arterial blood gases
03

In context

Pre-Eclampsia

916 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

This study's enrollment of 100 is close to the median of 110 across 480 interventional studies indexed under Pre-Eclampsia.

Browse Pre-Eclampsia studies →

Lead sponsor

Saint Thomas Hospital, Panama is the lead sponsor of 37 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gestational age: 24-40 weeks
  • Cases: Diagnosis of severe preeclampsia
  • Control: Normal blood pressure

Exclusion criteria

Exclusion Criteria:

  • Metabolic conditions that could hinder the results (diabetic ketoacidosis, sepsis, renal failure).
  • Clinical conditions that could hinder the results (diarrhea, vomit)
  • Recent use of bicarbonate
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Severe preeclampsia

    Pregnant subjects with severe preeclampsia

    Diagnostic Test: Arterial Blood gases

  • Experimental
    Normotensive

    Pregnant subjects with normal blood pressure

    Diagnostic Test: Arterial Blood gases

Interventions

  • Diagnostic testArterial Blood gases

    Determination of Excess Base in arterial blood gases before delivery / termination of pregnancy

06

What researchers measure

Primary outcomes

  1. Value of excess base

    Total measure of excess base measured by gasometry in an arterial blood sample

    Time frame: Immediately before delivery

  2. Hypertensive crisis

    Elevation of the blood pressure above 160 (systolic) and 110 (diastolic).

    Time frame: From admission to day three (3) after delivery

Secondary outcomes

  1. Lactate

    Concentration of lactate measured by gasometry in a sample of arterial blood.

    Time frame: Immediately before delivery

  2. Bicarbonate

    Concentration of bicarbonate measured by gasometry in arterial blood gases

    Time frame: Immediately before delivery

07

Study locations

1 site
  • Saint Thomas Hospital
    Panama City, Provincia de Panamá, Panama
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Feb 2026, 6 months.

Of 171 non-industry interventional studies with no phase under Pre-Eclampsia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's 6 months is below that.

Counting every sponsor, half of 176 studies reached it within 24 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2025
First posted
Dec 4, 2025
StartActual
Aug 15, 2025
Primary completionActual
Feb 20, 2026
CompletionActual
Mar 31, 2026
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07265336
Lead sponsor
Saint Thomas Hospital, Panama
Responsible party
Osvaldo A. Reyes T. (Head of Research Department, Saint Thomas Hospital, Panama) — Principal investigator
First posted
Dec 4, 2025
Start date
Aug 15, 2025
Primary completion
Feb 20, 2026
Completion
Mar 31, 2026
Last update
Jul 16, 2026

Study contacts

Osvaldo Reyes, MD
study chair · Saint Thomas Hospital, Panama

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion